The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test

被引:22
作者
Hascoët, M [1 ]
Bourin, M [1 ]
Dhonnchadha, BAN [1 ]
机构
[1] Fac Med Nantes, GIS Medicament, F-44035 Nantes, France
关键词
paroxetine; buspirone; 1-PP; anxiety; animal model; acute administration; 5-HT1A receptor; mice;
D O I
10.1016/S0091-3057(00)00293-8
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Although numerous animal procedures have been employed in the study of antidepressants (ADs) in anxiety, the results following acute administration remain highly variable. The present study investigated the effect of the SSRI paroxetine (4, 8, and 16 mg/kg, IF) in two tests of anxiety in mice: the light/dark test paradigm, and the four plates test (FPT). In both tests, it was found that paroxetine resulted in an anxiolytic - like effect at doses that did not modify motor performance (at the doses of 4 and 8 mg/kg in the light/dark test and at the doses of 4, 8, and 16 mg/kg in the four plates test). In the light/dark paradigm, both doses of buspirone significantly potentiated paroxetine, while in the four plates only one dose of buspirone (a 5HT(1A) partial agonist) (0.06 mg/kg) increased the anxiolytic-like effect of paroxetine. Prior administration of 1 -PP was without effect in the light/dark paradigm but antagonized the effect of paroxetine (at the dose of 0.06 and 0.5 mg/kg) in the FPT. The results suggested that a balance between pre- and postsynaptic 5 -HT1A receptor was implicated in the anxiolytic-like effect of paroxetine. Buspirone seemed to emphasize the role of paroxetine in 5-HT1A receptor modulation and exerted a biphasic influence in the two tests. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 48 条
[1]   EVALUATION OF RAPID TECHNIQUE FOR DETECTING MINOR TRANQUILIZERS [J].
ARON, C ;
SIMON, P ;
LAROUSSE, C ;
BOISSIER, JR .
NEUROPHARMACOLOGY, 1971, 10 (04) :459-&
[2]   A COMPARISON OF THE EFFECTS OF DIAZEPAM VERSUS SEVERAL TYPICAL AND ATYPICAL ANTI-DEPRESSANT DRUGS IN AN ANIMAL-MODEL OF ANXIETY [J].
BODNOFF, SR ;
SURANYICADOTTE, B ;
QUIRION, R ;
MEANEY, MJ .
PSYCHOPHARMACOLOGY, 1989, 97 (02) :277-279
[3]  
BODNOFF SR, 1988, PSYCHOPHARMACOLOGY, V95, P298
[4]  
BOURIN M, 1992, J PSYCHIATR NEUROSCI, V17, P72
[5]   A schematic representation of the psychopharmacological profile of antidepressants [J].
Bourin, M ;
Redrobe, JP ;
Hascoet, M ;
Baker, GB ;
Colombel, MC .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1996, 20 (08) :1389-1402
[6]   IDENTIFICATION AND QUANTITATION OF 1-(2-PYRIMIDINYL)PIPERAZINE, AN ACTIVE METABOLITE OF THE ANXIOLYTIC AGENT BUSPIRONE, IN RAT PLASMA AND BRAIN [J].
CACCIA, S ;
GARATTINI, S ;
MANCINELLI, A ;
MUGLIA, M .
JOURNAL OF CHROMATOGRAPHY, 1982, 252 (DEC) :310-314
[7]   DISPOSITION OF THE PSYCHOTROPIC-DRUGS BUSPIRONE, MJ-13805 AND PIRIBEDIL, AND OF THEIR COMMON ACTIVE METABOLITE 1-(2-PYRIMIDINYL)-PIPERAZINE IN THE RAT [J].
CACCIA, S ;
FONG, MH ;
GUISO, G .
XENOBIOTICA, 1985, 15 (10) :835-844
[8]   1-(2-PYRIMIDINYL)-PIPERAZINE AS ACTIVE METABOLITE OF BUSPIRONE IN MAN AND RAT [J].
CACCIA, S ;
CONTI, I ;
VIGANO, G ;
GARATTINI, S .
PHARMACOLOGY, 1986, 33 (01) :46-51
[9]   DISPOSITION AND METABOLISM OF BUSPIRONE AND ITS METABOLITE 1-(2-PYRIMIDINYL)-PIPERAZINE IN THE RAT [J].
CACCIA, S ;
MUGLIA, M ;
MANCINELLI, A ;
GARATTINI, S .
XENOBIOTICA, 1983, 13 (03) :147-153
[10]   ALPHA-2-ADRENOCEPTOR BLOCKADE PREVENTS THE EFFECT OF DESIPRAMINE IN THE FORCED SWIMMING TEST [J].
CERVO, L ;
GRIGNASCHI, G ;
SAMANIN, R .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 175 (03) :301-307